Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.
Ermens
A A
AA
Institute of Hematology Ee 2202, Erasmus University, Rotterdam, The Netherlands.
Lindemans
J
J
Abels
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004247:DNA / Q000096:biosynthesis; D003857:Deoxyuridine / Q000494:pharmacology; D005472:Fluorouracil / Q000627:therapeutic use; D005492:Folic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D013938:Thymidine Monophosphate / Q000096:biosynthesis; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013938:Thymidine Monophosphate; C031662:CB 3717; D004247:DNA; D005492:Folic Acid; D013940:Thymidylate Synthase; D005472:Fluorouracil; D003857:Deoxyuridine